Therefore, understanding the precise mechanisms underlying ALOX15B downregulation in KRAS‐mutant cancers may not only enhance the knowledge regarding the biological basis of KRAS mutation–mediated tumor initiation and progression but also enable the development of novel therapeutic strategies for patients with KRAS‐mutant cancers via pharmacological restoration of ALOX15B. The gene discussed is ALOX15B; the disease is neoplasm.